Physician profile
Jefferson B Alling
NPI 1477558245
$5,184.00
in general payments reported to CMS, 2019-2025
52 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $457 · 2021: $961 · 2022: $1,048 · 2023: $1,120 · 2024: $710 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,307.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $555.03 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $509.31 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $463.84 | 2021-2025 | Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $439.55 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.64 | 2020-2025 | Jardiance |
| Glaxosmithkline, LLC. | $367.47 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Antares Pharma, INC. | $293.90 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Astellas Pharma US INC | $162.41 | 2019-2025 | Veozah |
| Pfizer INC. | $148.19 | 2019-2025 | |
| Abbott Laboratories | $122.68 | 2023-2025 | Aveir, Freestyle Libre 3, Cardiomems |
| Dexcom, INC. | $107.52 | 2021-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $96.05 | 2020-2022 | |
| Sanofi Pasteur INC. | $89.20 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $80.17 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $77.78 | 2023-2024 | Quviviq |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jefferson Alling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.